Title |
Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer
|
---|---|
Published in |
BMC Cancer, April 2014
|
DOI | 10.1186/1471-2407-14-251 |
Pubmed ID | |
Authors |
Danhong Wang, Bin Zhang, Haiyan Gao, Guoliang Ding, Qiong Wu, Jinchao Zhang, Li Liao, Hu Chen |
Abstract |
Renal cell carcinoma (RCC) is a malignant disease that demonstrates resistance to standard chemotherapeutic agents. Yet Active immunization using genetically modified dendritic cells holds promise for the adjuvant treatment of malignancies to eradicate or control residual disease. Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8+ T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities against tumor cells. Clinical studies have confirmed benefit and safety of CIK cell-based therapy for patients with malignancies. This clinical trial was conducted to evaluate efficacy and safety of genetically modified dendritic cells in combination with Cytokine-Induced Killer Cell (gmDCs-CIK) treatment of patients with RCC. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 40 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 6 | 15% |
Student > Bachelor | 6 | 15% |
Student > Master | 6 | 15% |
Student > Ph. D. Student | 5 | 13% |
Student > Doctoral Student | 2 | 5% |
Other | 5 | 13% |
Unknown | 10 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 33% |
Agricultural and Biological Sciences | 4 | 10% |
Nursing and Health Professions | 3 | 8% |
Biochemistry, Genetics and Molecular Biology | 2 | 5% |
Immunology and Microbiology | 2 | 5% |
Other | 4 | 10% |
Unknown | 12 | 30% |